Login
$STAA
$26.01 -$0.38 (1.44%) Live

$STAA 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Adjusted EBITDA[1]of $14.4 Million, or $0.28 per Diluted Share

10 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market

12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

06 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Partici...

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This Amendment No. 2 (the “Amendment No. 2”) to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “Plan”) is adopted by the Board of Directors (“Board”) of STAAR Surgical Company, a Delaware corporation (...

09 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 8, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of STAAR Surgical Company (the “Company”) approved an increase to the annual base salary of Deborah Andrews, the Company's Interim Co-Chief Executive...

13 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share

08 Apr 2026 8-K: Regulation FD Disclosure

LAKE FOREST, CA, April 8, 2026 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for th...

03 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation

05 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

On February 4, 2026, STAAR Surgical Company (the “Company”) entered into a letter agreement with Nathaniel Sisitsky, the Company’s Chief Legal Officer and Corporate Secretary (the “Letter Agreement”), that provides for Mr. Sisitsky’s ter...

02 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Lake Forest, CA, February 2, 2026 --- STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announce...

16 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 15, 2026, the Board of Directors (the “Board”) of STAAR Surgical Company (the “Company”) elected a new Board Chair, approved changes to the composition and leadership of the Board’s three standing committees, and established t...

15 Jan 2026 8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule +2 more

This letter agreement (this “Agreement”), effective as of January 14, 2026 (the “Effective Date”), is intended to memorialize the understandings and agreements that have been reached between STAAR Surgical Company (the “Company”) and Bro...

06 Jan 2026 8-K: Termination of a Material Definitive Agreement; Submission of Matters to a Vote of Security Holders

As previously disclosed, on August 4, 2025, STAAR Surgical Company (the “Company”) entered into an Agreement and Plan of Merger, dated as of August 4, 2025 (as amended, the “Merger Agreement”), by and among the Company, Alcon Research, L...

06 Jan 2026 8-K: Other Events

LAKE FOREST, CA, January 6, 2026 – STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminar...

09 Dec 2025 8-K: Entry into a Material Definitive Agreement

This Amendment No. 2, dated as of December 9, 2025 (this “Amendment”), to the Agreement and Plan of Merger, dated as of August 4, 2025 (the “Initial Agreement”), as amended, is by and among Alcon Research, LLC, a Delaware limited liabili...

08 Dec 2025 8-K: Other Events

Results of Go-Shop Process Validate the Effectiveness of the STAAR Board’s Process

07 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

This Amendment No. 1, dated as of November 7, 2025 (this “Amendment”), to the Agreement and Plan of Merger, dated as of August 4, 2025 (the “Agreement”), is by and among Alcon Research, LLC, a Delaware limited liability company (“Parent”...

05 Nov 2025 8-K: Results of Operations and Financial Condition

LAKE FOREST, CA, November 5, 2025 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quar...

27 Oct 2025 8-K: Other Events

STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support